Skip to main content

Advertisement

SpringerLink
Log in

Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Gastric cancer (GC) is one of the most threatening diseases. The symptoms of GC are complex and hard to detect, which also contribute to the poor prognosis of GC. Besides, the current diagnosis for GC is expensive and invasive. Thus, a fast, noninvasive biomarker is urgently needed for GC screening. MicroRNAs (miRNAs) are small noncoding RNAs, which are involved in a great variety of pathological processes, particularly carcinogenesis. MiRNAs are stable in gastric juice, plasma as well as serum, which facilitate it to be a promising biomarker for cancer. In this study, we selected three novel miRNAs, i.e., miR-233, miR-16, and miR-100, to investigate their potential diagnostic value in GC screening. A total of 50 GC patients and 47 healthy controls were involved in this study. Blood serum samples were collected; RNAs were extracted and normalized with U6 snRNA as the internal control; qRT-PCR was performed for relative expression of target miRNAs. Levels of miRNAs expression were compared by Student’s t test for the comparison between two groups, and one-way ANOVA was used for multiple comparisons. The expression of miR-223, miR-16, and miR-100 was all significantly higher in GC patients than controls (all P < 0.001). All the tested miRNAs were manifested to be valuable biomarkers for GC. Relative expression of these miRNAs was significantly correlated with clinical characteristics of GC patients, such as TNM stage (P = 0.036 for miR-223; P < 0.001 for miR-100), metastatic status (P = 0.045 for miR-223; P = 0.031 for miR-16; P = 0.006 for miR-100), tumor size (P = 0.042 for miR-223; P = 0.031 for miR-16; P < 0.001 for miR-100), and differentiation grade (P = 0.036 for miR-223; P = 0.030 for miR-16; P = 0.034 for miR-100). However, in T classification, which considered both tumor size and direct extent of primary tumor, the difference in target miRNAs expression was not significant. In summary, we confirmed the diagnostic value of serum miR-223, miR-16, and miR-100 in GC. Significantly elevated expression of the three miRNAs was also observed in advanced GC patients, which suggested their availability in cancer staging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  3. D’Angelo G, Di Rienzo T, Ojetti V. Microarray analysis in gastric cancer: a review. World J Gastroenterol. 2014;20(34):11972–6.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Ebert MP, Rocken C. Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol. 2006;18(8):847–53.

    Article  CAS  PubMed  Google Scholar 

  5. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–24.

    Article  CAS  PubMed  Google Scholar 

  6. Rasheed SAK, Teo CR, Beillard EJ, Voorhoeve PM, Casey PJ. microRNA-182 and microRNA-200a control G-protein subunit α-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. J Biol Chem. 2013;288(11):7986–95.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, et al. microRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell. 2014;25(4):469–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Yang Y, Peng W, Tang T, Xia L, Wang XD, Duan BF, et al. MicroRNAs as promising biomarkers for tumor-staging: evaluation of miR21 miR155 miR29a and miR92a in predicting tumor stage of rectal cancer. Asian Pac J Cancer Prev. 2014;15(13):5175.

    Article  PubMed  Google Scholar 

  9. Wittekind C, Asamura H, Sobin LH. TNM Atlas. London: John Wiley & Sons; 2014.

    Book  Google Scholar 

  10. Cui L, Zhang X, Ye G, Zheng T, Song H, Deng H, et al. Gastric juice microRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 2013;119(9):1618–26.

    Article  CAS  PubMed  Google Scholar 

  11. Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, et al. MiRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol. 2013;20(3):397–405.

    Article  Google Scholar 

  12. Cai H, Yuan Y, Hao Y-F, Guo T-K, Wei X, Zhang Y-M. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol. 2013;30(1):1–7.

    Article  Google Scholar 

  13. Nishizawa T, Suzuki H. The role of microRNA in gastric malignancy. Int J Mol Sci. 2013;14(5):9487–96.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Mishra S, Lin CL, Huang TH, Bouamar H, Sun LZ. microRNA-21 inhibits p57Kip2 expression in prostate cancer. Mol Cancer. 2014;13(1):212.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z et al. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Kruppel-like factor 4. Cancer Lett. 2014;355(1):85–95.

  16. Leung CM, Tsai KW, Pan HW. DNA methylation in aggressive gastric carcinoma. 2013;223–242. doi:10.5772/52135.

  17. Crone SG, Jacobsen A, Federspiel B, Bardram L, Krogh A, Lund AH, et al. microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-kappaB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer. 2012;11:71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Ma L, Chen Y, Zhang B, Liu G. Increased microRNA-223 in Helicobacter pylori-associated gastric cancer contributed to cancer cell proliferation and migration. Biosci Biotechnol Biochem. 2014;78(4):602–8.

    Article  CAS  PubMed  Google Scholar 

  19. Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW, et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One. 2012;7(3):e33919.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Li J, Guo Y, Liang X, Sun M, Wang G, De W, et al. microRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol. 2012;138(5):763–74.

    Article  CAS  PubMed  Google Scholar 

  21. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. MiRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 2011;9(7):824–33.

    Article  CAS  PubMed  Google Scholar 

  22. Shin VY, Jin H, Ng EK, Cheng AS, Chong WW, Wong CY, et al. NF-kappaB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. Carcinogenesis. 2011;32(2):240–5.

    Article  CAS  PubMed  Google Scholar 

  23. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, et al. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer J Int Du Cancer. 2008;123(2):372–9.

    Article  CAS  Google Scholar 

  24. Sun H, Meng X, Han J, Zhang Z, Wang B, Bai X, et al. Anti-cancer activity of DHA on gastric cancer–an in vitro and in vivo study. Tumour Biol. 2013;34(6):3791–800.

    Article  CAS  PubMed  Google Scholar 

  25. Wang M, Ren D, Guo W, Wang Z, Huang S, Du H, et al. Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2. Int J Oncol. 2014;45(1):362–72.

    CAS  PubMed  Google Scholar 

  26. Peng H, Luo J, Hao H, Hu J, Xie SK, Ren D, et al. microRNA-100 regulates SW620 colorectal cancer cell proliferation and invasion by targeting RAP1B. Oncol Rep. 2014;31(5):2055–62.

    CAS  PubMed  Google Scholar 

  27. Shi DB, Xing AY, Gao C, Gao P. Expression of microRNA-100 in human gastric cancer. Zhonghua Bing Li Xue Za Zhi Chin J Pathol. 2013;42(1):15–9.

    CAS  Google Scholar 

  28. Mroczek S, Dziembowski A. U6 RNA biogenesis and disease association. Wiley Interdiscip Rev RNA. 2013;4(5):581–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant from National Natural Science Foundation of China (Grant No. 81101504.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Vascular and Endocrine Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, 710032, Shanxi Province, China

    Hui Wang, Lei Wang, Rui Ling, Jun Yi, Ling Wang, Jiefang Bian, Jianghao Chen, Nanlin Li, Shifang Yuan & Jun Yun

  2. Department of Biotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei Province, China

    Zheng Wu

  3. Department of Gastroenterology, Bethune International Peace Hospital, Shijiazhuang, 050082, Hebei Province, China

    Rong Sun & Haifeng Jin

  4. Department of Information, Bethune International Peace Hospital, 398 Zhongshan Western Road, Shijiazhuang, 050082, Hebei Province, China

    Jifeng Ma

  5. Department of Oncology, Tangdu Hospital, the Fourth Military Medical University, Xi’an, China

    Lili Liu

Authors
  1. Hui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zheng Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haifeng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jifeng Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lili Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rui Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jun Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ling Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jiefang Bian
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jianghao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Nanlin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shifang Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jun Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Shifang Yuan or Jun Yun.

Additional information

H. Wang, L. Wang and Z. Wu are the co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, H., Wang, L., Wu, Z. et al. Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med Oncol 31, 298 (2014). https://doi.org/10.1007/s12032-014-0298-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0298-8

Keywords

Search

Navigation